Lipids play an important part as risk or protective factors for Alzheimer's disease. This review summarizes the current findings in which lipids influence Alzheimer's disease and introduces the molecular mechanism how these lipids are linked to amyloid production. Besides the pathological impact of amyloid in Alzheimer's disease, amyloid has a physiological function in regulating lipid homeostasis in return. The understanding of the resulting regulatory cycles between amyloid precursor protein processing and lipids provides a platform for the development of new causal therapeutic approaches for Alzheimer's disease.
Alzheimer's disease
Alzheimer's disease (AD) is one of the most common forms of dementia, affecting up to 15 million people world wide. Above 60 years prevalence doubles every 5 years. 1% of individuals of 60-64 years suffer from AD. A percentage that increases up to 40% of those who get older than 85 years. In an aging population in which both, life expectancy and the average age is increased, the ethical and the economical relevance is going to increase even more [1, 2] .
The main characteristics of AD are massive cerebral accumulation of amyloid composed of fibrillary aggregates of the amyloid beta peptide (Aβ) and intracellular accumulation of abnormally phosphorylated Tau protein leading to widespread neurodegeneration. The clinical picture is characterized by progressive and irreversible dementia, which is eventually fatal (for reviews see [3] [4] [5] [6] ).
APP processing
Aβ is a proteolytic fragment of the larger amyloid precursor protein (APP). The processing of APP is summarized in Fig. 1 .
APP can be cleaved by two different ways. α-secretase initiates the non amyloidogenic pathway and results in the cleavage of APP within the Aβ domain, thus precluding the generation of Aβ. Cleavage of APP by α-secretase yields α-secreted APP (sAPPα) and the remaining membrane-bound Cterminal fragment α-CTF. Alternatively, the BACE-catalyzed β-cleavage of APP initiates Aβ generation and the amyloidogenic pathway. BACE cleavage results in β-secreted APP (sAPPβ) and the C-terminal fragment β-CTF of APP. Both membrane-bound C-terminal fragments of APP, α-CTF and β-CTF, are substrates for γ-secretase, a ubiquitous multimeric protease. The γ-secretase cleavage of α-CTF results in the generation of a truncated non-amyloidogenic peptide (p3), whereas γ-secretase cleavage of β-CTF leads to the generation of Aβ, the main proteinaceous component of the amyloid plaques found in brains of patients with AD. As β-CTF can be cleaved at different sides by γ-secretase, Aβ varies in length; mainly a 40 amino acid (aa) long peptide Aβ40 and a peptide Fig. 1 . Non-amyloidogenic and amyloidogenic processing of APP by α-, β-and γ-secretases. Schematic representation of APP and its proteolytic fragments α-secreted APP (sAPPα), β-secreted APP (sAPPβ), α-CTF, β-CTF, p3 and Aβ. Cleavage sites of α-, β-and γ-secretases are shown. which is 2 aa longer, Aβ42, are produced. Because of its increased hydrophobicity Aβ42 is able to build aggregates and is the predominant species of Aβ in senile plaques [7] . Both in amyloidogenic and non-amyloidogenic pathway γ-secretase cleavage results in the production of the APP intracellular domain (AICD), which is reported to activate gene transcription in the nucleus [8] .
In addition, studies on the infrequent familial forms of Alzheimer's disease (FAD) indicate increased production of Aβ42 to be invariably associated with FAD and to cause AD [3, 4, [9] [10] [11] . Moreover, age of disease onset correlates directly with the Aβ40/42 ratio [12] .
3. γ-secretase and regulated intramembrane proteolysis γ-secretase is a multienzyme complex consisting up of at least the proteins presenilin 1 (PS1), presenilin 2 (PS2), APH1, PEN2 and Nicastrin [13] .
The knock-out of both presenilins, PS1 and PS2, or the mutation of the aspartatic residues D257 and D385 result in complete loss of γ-secretase activity and Aβ production [14, 15] , identifying the presenilins as active centre of the γ-secretase complex.
Importantly, the γ-cleavage site of β-CTF is located in the centre of the transmembrane domain of APP/β-CTF, possibly causing sensitivity to alterations in membrane composition [16] . Such proteolytic events of regulated intramembrane proteolysis (RIP) are involved in a number of cellular regulatory events including lipid homeostasis [17] [18] [19] [20] [21] [22] [23] .
Cholesterol and brain
The brain is one of the most cholesterol-rich organs. Cholesterol is an essential factor of cell membranes and plays a crucial role in the development and maintenance of neuronal plasticity and function [24] . The homeostasis of cholesterol including synthesis, removal, storage or transport in brain is strictly regulated. One of the key enzymes in the biosynthetic pathway of cholesterol (see Fig. 2 ) is the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) which catalyzes the formation of mevalonate [25] . As this enzyme catalyzes the rate limiting and committed step of the cholesterol biosynthesis, HMGR is both a target for the physiological regulation of the cholesterol homeostasis and for pharmacological inhibitors (e.g. statins) [26] .
In mature neurons endogenous cholesterol synthesis is reduced and surplus cholesterol required for synaptic plasticity is believed to be supplied by glial cells, primarily astrocytes [27] . Most cholesterol used in the brain is synthesized in the CNS and transport of cholesterol from peripheral circulation to brain is prevented by an intact blood-brain barrier (only the oxidized cholesterol products 27-hydroxycholesterol and 24S-hydroxycholesterol [28] can pass the blood-brain barrier). The exchange rate between peripheral and brain cholesterol is approximately 1% per day. Therefore it has to be assumed that cholesterol homeostasis of the brain is not completely independent of blood cholesterol level [29] .
Cholesterol and APP
Until recently little indication existed, suggesting a link between AD, APP processing and cholesterol homeostasis. However, this picture changed dramatically over the last years [30] [31] [32] [33] . First indications that lipids may play an important role in APP processing and Aβ production are given by the fact that all proteins involved in processing are integral membrane proteins. Taking into consideration that the Aβ generating cleavage by the γ-secretase takes place in the middle of the membrane, it is reasonable to assume that the lipid environment of the cleavage enzymes influences Aβ production and hence AD pathogenesis [16] .
Cellular and biochemical studies indeed show that APP processing and the proteases involved are sensitive to cholesterol and cholesterol trafficking [34] [35] [36] [37] [38] [39] [40] [41] [42] . In vitro enhanced cholesterol levels lead to increased Aβ production [34] . Controversially, one report found a correlation between mildly decreased cholesterol levels and increased Aβ production in Chinese hamster ovary (CHO) cells [43] . In vivo studies revealed that cholesterol feeding increases Aβ42 production and amyloid burden whereas lowering cholesterol by medication (e.g. statins) decreases Aβ production and amyloid burden [37, [44] [45] [46] .
Likewise, the relevance of cholesterol homeostasis in AD was further substantiated in epidemiological studies [47, 48] . There is an interesting link to the predominant AD risk gene apolipoprotein E (ApoE) and AD [49, 50] , because this may involve its function as a lipid transporting protein. However, the molecular mechanism by which the disease linked allele ε4 of ApoE causes earlier disease onset remains currently unresolved. Moreover, an early increase in brain cholesterol levels during disease progression [51] and studies on lipid composition in AD brains [52] further support the importance of cholesterol and lipids in AD.
Accordingly statin treatment is associated with a reduced AD risk in some epidemiological studies [53] [54] [55] . The first preliminary clinical trial came out with mixed results. High statin dosage reduced cerebral Aβ levels and disease progression in mild AD [56] . When treatment duration was doubled beneficial effects were observed in mild and moderate AD [57] . However, low statin dosage treatment for up to 12 months did not show some potential secretase inhibition and clinical benefits [58, 59] .
Important molecular evidence includes that cholesterol enhance γ-secretase mediated Aβ production in vitro [34, 36, 37, 41, 60] , whereas inhibition of HMGR reduces Aβ levels in cerebrospinal fluid and brain tissue [37] . Inhibition of 7-dehydro-cholesterol-reductase, which catalyzes the final step of cholesterol biosynthesis, decreases amyloid load [46] and cholesteryl-esters stimulate non-amyloidogenic APP degradation [61] . The Aβ generating machinery is highly responsive to small alterations in lipid or cholesterol composition [34, 36, 37, 41] and even small changes that are induced by altering the standard mouse diet to a cholesterol enriched diet causes increased cerebral amyloid load [44, 45] . Moreover, Aβ binds cholesterol [62] .
While dietary approaches and inhibition of cholesterol synthesis by BM15.766 revealed that cholesterol modulates Aβ levels in animals, the situation is apparently more complex for the statin effect in mouse brains. In some studies statins reduce Aβ, while some other studies find no effect on Aβ production. In addition one study reported even an increased Aβ production in female, but not in male mice. In mouse brains statins did not show the expected change in cholesterol metabolism or Aβ production, but an anti-inflammatory effect, sometimes combined with improved cognitive performance [63] [64] [65] [66] [67] . Some data indicate that this may be related to the way how statins effect cholesterol metabolism in mouse brains. Lutjohann [68] reported that in contrast to the lipophobic pravastatin the lipophilic simvastatin reduced brain cholesterol and increased HMGR expression. Both statins seem to change cholesterol metabolism in guinea pigs [68, 69] . A possible explanation for this is that guinea pigs might be more closely related to the human brain lipid physiology. This is unfortunate, because transgenic mice otherwise represent a most valuable tool to study Alzheimer's disease in animal models [70] [71] [72] [73] . Another conclusion from the difficulties with statins in mice is of course that effects on Aβ production were only observed when it coincided with a parallel change in cholesterol metabolism. As much as this and the other studies point out that cholesterol is critically involved in Aβ generation little is known about the mechanism by which cholesterol affects APP processing.
Gangliosides and APP
Gangliosides are glycosphingolipids, which are mainly found in the outer leaflet of mammalian plasma membranes and are enriched in membranes of nervous system. GM1, GD1a, GT1b and GD1b are the group of major gangliosides found in brain [74] . It has been shown that an increased sialidase activity, resulting in an increase of GM1, is found in brains of AD patients [75, 76] . Further studies revealed a changed ganglioside pattern in AD brain emphasizing the importance of glycosphingolipids for AD [77] . GM1 has been detected in amyloid plaques bound to Aβ [78] . As a model it was suggested that GM1-bound Aβ complexes can serve as a seed for toxic amyloid fibril formation leading to neuronal death. Moreover, an effect of GM1 on Aβ production was observed [79] . Whereas γ-secretase activity seemed to be increased by incubation of GM1 the non-amyloidogenic α-secretase was reported to be decreased in the presence of GM1 [79] . Mechanistically it seems to be possible that GM1 decreases sAPPα secretion by inhibition of protein kinase C (PKC), which positively regulates α-cleavage [80] . Another explanation was given by the stiffening effect of GM1 on membranes. In this model the inhibited lateral movement and the reduced required contact between substrate and enzyme is pointed out.
In vitro experiments indicated that in addition glycosphingolipids are involved in the transport of APP in the secretory pathway and its expression on the cell surface and thereby altering the proteolytic processing of APP [81] . Apparently cholesterol is the most obvious but by far not the only lipid with relevance to AD.
Lipid-rafts and AD
As summarized above both cholesterol and gangliosides, especially GM1, drastically increases Aβ production. One of the common characteristics between gangliosides and cholesterol is that these lipids are major components of rafts.
Rafts are a concept of lipid microdomains that introduce lateral heterogeneity into the membrane layer. It is assumed that they represent ordered platforms that float in the liquiddisordered matrix of the cellular membrane and form devices to compartmentalize membrane processes. Biochemically rafts can be characterized by their insolubility in detergents (e.g. Triton X-100 or CHAPS) at 4°C [82, 83] . These detergent resistant membranes (DRM) are involved in modulating cellular function and cellular structures [84] [85] [86] [87] including APP processing [60, [88] [89] [90] [91] [92] [93] . BACE I and γ-secretase or PS respectively are also present in rafts [88, 89, [91] [92] [93] [94] . On the other hand it could be shown that ADAM 10, which is a putative α-secretase, was soluble after detergent extraction [95] . These findings could be explained by a hypothetical model that APP might be present in two different pools in the membrane. The first pool is associated with rafts, where the amyloidogenic pathway could take place and Aβ is produced. The second APP pool in this model is localized outside the DRM, where α-cleavage takes place. The advantage of this model is that it could explain how the same protein could be processed in two exclusive ways by separating substrate and the different enzymes in different membrane microdomains.
Sphingolipids and APP processing
Besides cholesterol and gangliosides, sphingolipids, in particular sphingomyelin (SM), play an important role in raft biology [96] .
Sphingolipids are generated by the condensation of palmitoyl-coenzymA and L-serine (by serine-palmitoyl-transferase (SPT)) resulting in 3-dehydrosphinganine, which is metabolized via several enzymes to ceramide (Cer) (see Fig. 3 ). Cer is one of the most important branching point of this metabolic pathway. Glycosylation of Cer leads to the glycosphingolipids, the ceramidase catalyzes the reaction yielding in sphingosin and the sphingomyelin-synthase metabolizes Cer to sphingomyelin [97] .
Elimination or inhibition of the entire sphingolipid biosynthesis at the level of the SPT has drastic effects on APP processing. In CHO-cells α-secretase cleavage increases with the concomitant accumulation of secretory APP. At the same time ε-cleavage decreases while Aβ42 levels increase. Aβ40 levels and β-cleavage remains unaltered [98] . It is currently difficult to judge which molecular mechanism are responsible for those effects. A possible explanation might be that SPT absence results in multiple cellular changes, including absence of ceramide, ganglioside and sphingosin production. As mentioned above, the elimination of gangliosides alone is sufficient to distort APP trafficking and hence APP processing. Interestingly, the APP processing phenotype could be partly restored in SPT activity deficient cells by inhibiting MAPK kinase, suggesting an involvement of the MAPK/ERK pathway [98] .
As expected cellular responses differ when instead of the sphingolipid pathway specific lipids are targeted and analyzed for their effect on APP processing. In contrast to cholesterol and gangliosides, SM decreases Aβ production by inhibition of the γ-secretase [99] . This surprising result was confirmed by sphingomyelinase (SMase) inhibition experiments. SMases are enzymes that break down SM to Cer. Inhibition of these degrading enzymes lead to increased SM levels and decreased Aβ-level. Interestingly, SMase activity is increased in PS-FAD mutations, which may indicate a role of SMases in AD [99] . The molecular mechanism how SM decrease γ-cleavage of APP is unknown. One of many possibilities would be that SM interacts with the γ-secretase complex lowering its activity. Such a situation may exist for BACE I interaction. SM and gangliosides increase BACE activity when present in synthetic lipid vesicles, but activity is further increased when replaced by cerebrosides, but it is unknown whether this interaction is direct [100] . Locally, a given lipid may therefore not work unilaterally, but rather its effect is determined by concentration and composition of the lipid mixture with which it forms the membrane domain analyzed. This is also important in the context of a possible contradiction between these findings and the above described raft model. Whereas cholesterol, gangliosides and SM are major components of rafts, only SM decreases γ-secretase activity. This difference might be based on the fact that sphingolipids, in particular SM, lower plasma cholesterol [101] , increased SM production may therefore change raft properties unfavourably for γ-cleavage. Furthermore, SM has a strong tendency to bind to cholesterol which might influence APP processing further.
In addition to SM there is a link of other sphingolipids to AD as well. Sphingosin is considered to affect PKC [102] and therefore influences α-secretase. Cer can modulate a variety of cellular effects ranging from proliferation and differentiation to growth arrest and apoptosis [103] . Cer induced apoptosis might play an important role under pathological conditions such as in AD [104] . On account of these examples an additional mechanism of the described lipids is pointed out. Besides an influence of lipids on APP processing by influencing the lipid environment, bioactive (sphingo-)lipids serve as highly regulated second messenger in cascades interfering with AD. Although several aspects remain unclear, the aforementioned and further augmenting evidence suggests, that the link between lipids and AD aetiopathology is substantial and comprehensive. However, missing in this scheme is a functional link that elucidates the specific lipid sensitivity of this proteolytic system.
APP processing and cholesterol metabolism, a regulatory feedback cycle
The above mentioned findings summarize that some lipid classes are able to influence APP processing and therefore affect Aβ-production and AD. First indications that not only lipids influence APP processing but APP processing also influences lipid metabolism were given by the fact that in absence of PS membrane fluidity is decreased [105] . As cholesterol has a condensing effect on membranes [106] and is an important regulator of membrane fluidity, indications were given that Fig. 3 . Sphingolipid biosynthesis. The biochemical pathway illustrates the sphingolipid biosynthesis beginning with the rate limiting enzyme serine-palmitoyl-CoAtransferase (SPT). Starting from the branching point ceramide, sphingomyelin, glycosphingolipids and sphingosin can be synthesized. A crucial role in ceramide/SM homeostasis plays the SM degrading enzyme SMase. Fig. 4 . Model of the feedback regulation between cholesterol homeostasis and APP processing. Cholesterol increases γ-secretase activity, which leads to an increased Aβ production. In return Aβ downregulates cholesterol de novo synthesis leading to a regulatory cycle.
γ-secretase activity may alter cholesterol levels. Indeed in PS deficient fibroblasts cholesterol levels are increased. These results were reproduced in mice brain, where PS is conditionally knocked out, emphasizing the in vivo relevance of this finding. Moreover, in vivo and in vitro, it could be shown that the absence of the γ-secretase substrate APP results in virtually the Fig. 5 . Comparison of cholesterol regulation via SREBP/SCAP system and APP processing. In both systems cholesterol influences the regulated intramembrane proteolysis (RIP). Whereas cholesterol inhibits S1P cleavage in the SREBP system APP processing by γ-secretase is enhanced by cholesterol. Similarly the proteolytic cleavage products of this regulation results in decreased Aβ40 or increased SREBP S1P cleavage leading both to increased cholesterol synthesis. This results in a regulatory cascade, which allows to adjust the cholesterol homeostasis. Fig. 6 . Model of the feed forward regulatory cycle between sphingolipids and APP processing. Sphingomyelin decreases γ-secretase activity and in return reduced γ-secretase activity leads to an decreased nSMase activity and therefore an increased SM level. SMase and SM-synthase are regulated inversely. For SMase a direct regulation of Aβ42 on nSMase could be shown. same cholesterol increase. In addition PS-FAD mutations with increased Aβ42 and decreased Aβ40 levels show an increased cholesterol level, too [99] . This suggests that Aβ40 inhibits cholesterol synthesis. In line with these results PS deficient cells incubated with Aβ40 show decreased HMGR activity and decreased cholesterol level. Taken together this suggests a negative feed back cycle (see Fig. 4 ).
On one hand cholesterol increases γ-secretase activity and Aβ-production, on the other hand Aβ, especially Aβ40, decreases HMGR-activity and cholesterol synthesis. Whether this regulation of the HMGR by Aβ40 is direct or mediated via another metabolite is currently unclear. Because of the localization of the HMGR in the membrane of the endoplasmatic reticulum (ER) [107] , both options seem to be possible, but due to the low Aβ40 level in the ER [108] , a signal transmission via another metabolite might be preferred.
Analogies of the SREBP and APP lipid regulatory systems
Following the discovery of the lipid-controlled RIP mechanism of the sterol regulatory element binding protein (SREBP) with site-1 protease (S1P) and site-2 protease (S2P), this represents a second proteolytic system in lipid homeostasis (see Fig. 5 ). Whereas high cholesterol inhibits S1P cleavage of SREBP and therefore the transcription of the cholesterol synthesizing enzyme HMGR [109] , cholesterol increases γ-secretase cleavage of APP, resulting in high Aβ levels, which inactivate HMGR enzyme activity.
Although there are no sequence homologies, the functional analogies to the system presented here are striking. Both systems act via HMGR, but an important difference is that APP processing reduces, whereas SREBP processing upregulates cholesterol de novo synthesis. In a further analogy, the example of S2P suggests that not all γ-secretase substrates are processed lipid-dependently.
APP processing regulates sphingolipid homeostasis
A further regulatory cycle between APP processing and sphingolipid homeostasis was observed. As summarized above, in contrast to cholesterol sphingomyelin decreases γ-secretase activity and Aβ-production. On the other hand both, PS or APP deficiency, results in increased SM levels [99] (see Fig. 6 ).
It could be demonstrated that Aβ in particular Aβ42, directly activates the neutral SMase (nSMase), the SM degrading enzyme. In line with this finding PS-FAD mutations with an increased Aβ42 ratio showed an increased nSMase activity and therefore a corresponding decreased SM level. Again a physiological function of Aβ is linked to pathological processes in AD by this finding.
Whereas under physiological conditions an effect of Aβ to the SMase via reactive oxidative species (ROS) could be excluded, under pathological conditions with highly increased Aβ levels ROS may play an active part in the activation of the SMase [110] . Under these conditions an accumulation of the degradation product of SM, the second messenger Cer could be relevant for neuronal survival as Cer can serve as an apoptotic mediator [111] .
Many questions remain unanswered by this short review. But almost entirely neglected for more than 80 years of AD research, lipid biology has become one of the most attractive and fastest advancing fields in AD research. The hope is now that this will lead to effective therapeutic and preventive treatments for AD. There is reason to believe that this hope is not entirely unsubstantiated. With several ongoing lipid metabolism targeting clinical trials, major advances in the understanding of the molecular mechanism and most recently with the discovery of the physiological basis of Aβ generation as essential part of a complex lipid homeostasis regulatory cascade, the field appears at least to be on a promising track.
